This opens the question=what other cell therapy products can come to the market under 361. For exa=ple we believe the stromal vascular fraction that IntellicellBioscience (S=FC) qualifies under these rules. 0Our conclusion:<=b>Under this regulatory framework, companies can claim that =hat a product meets the "361" re